Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4267649 | 0.91 | GAA (0.55) | GAAADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4263637 | 0.89 | GAA (0.53) | GAAADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4272840 | 0.85 | GAA (0.52) | GAAADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4267000 | 0.85 | GAA (0.51) | GAAADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4260231 | 0.84 | GAA (0.50) | GAAADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4262459 | 0.84 | GAA (0.50) | GAAADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4265738 | 0.84 | GAA (0.50) | GAAADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4262403 | 0.84 | GAA (0.52) | GAAADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4259906 | 0.84 | GAA (0.50) | GAAADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4269971 | 0.83 | GAA (0.62) | GAAADORA3ADORA1ADORA2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | GAA 1001/4885ADORA3 591/4885ADORA1 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.